We’re in the news… The Korean Herald

Exclusive: SK Pharmteco’s French CDMO to complete construction of new plant in Q1 2023

Yposkesi CEO Alain Lamproye says 2nd plant expected to begin operation at start of 2024.

FRANKFURT, Germany — Yposkesi, SK Pharmteco’s French contract development and manufacturing organization specialized in cell and gene therapy, is expecting to complete the construction of its new plant by the end of the first quarter next year, the CDMO’s CEO said Tuesday.

“After (the completion of the plant), we will qualify this manufacturing unit and we expect to get the authorization from the French authorities to operate the plant under the (Good Manufacturing Practice) by the end of next year,” Alain Lamproye, CEO of Yposkesi, told The Korea Herald in an interview on the sidelines of this year’s Convention on Pharmaceutical Ingredients in Frankfurt, Germany.

Lamproye added that the company should be able to operate the new plant for customers at the beginning of 2024.

Tap below to read full story.


Scroll to Top

Enter your details to access Marketing Materials